Affiliation:
1. Kantar, Health Division, 175 Greenwich St, WTC 3, 35th Floor, NY 10007, USA
Abstract
Aim: To report the results of a survey of USA physicians (CancerMPact) that treat non-small-cell lung cancer patients. Materials & methods: 60 physicians were surveyed. Questions covered aspects of the treatment for all stages of the disease. Results: For stage I patients, over 70% of the treatments were based on surgery. For stage II/III disease, a strong preference for combined therapy (surgery/radiation/systemic therapy) was observed. For advanced/stage IV patients, physicians used systemic therapy alone, and choosed the regimen based on histology and biomarkers. Use of PD-L1 inhibitors was highly dependent on histology and biomarkers. Conclusion: The treatment choices of non-small-cell lung cancer are increasingly complex, involve different treatment modalities and are highly dependent on histology and biomarkers, besides stage.
Subject
Cancer Research,Oncology,General Medicine
Reference14 articles.
1. Cancer Facts and Figures 2019 (2020). www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2019/cancer-facts-and-figures-2019.pdf
2. CancerMPact Patient Metrics Database (2020). www.cancermpact.com
3. Lung cancer survival in the United States by race and stage (2001-2009): Findings from the CONCORD-2 study
4. A review of guidelines for lung cancer
5. Lung cancer: current therapies and new targeted treatments
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献